Jusdap-M 500 Tablet ER is a fixed-dose combination medication containing Dapagliflozin 10 mg and Metformin 500 mg extended-release, indicated for the management of type 2 diabetes mellitus. Dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces renal glucose reabsorption, promoting urinary glucose excretion and thereby lowering plasma glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control. The extended-release formulation allows for once-daily dosing, improving patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Jusdap-M 500 is recommended as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on either agent alone or in combination with other antidiabetic medications. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Common adverse effects include urinary tract infections, genital mycotic infections, gastrointestinal disturbances, and potential risk of hypoglycemia when used with insulin or insulin secretagogues. Regular monitoring of renal function, blood glucose, and signs of ketoacidosis is essential during therapy. Jusdap-M 500 should be prescribed under medical supervision with appropriate patient education on lifestyle modifications and adherence.